頁籤選單縮合
題 名 | 免疫療法的絆腳石:irAEs=A Stumbling Block to Immunotherapy: irAEs |
---|---|
作 者 | 許育瑋; 蔡佩芬; | 書刊名 | 藥學雜誌 |
卷 期 | 36:1=142 2020.03[民109.03] |
頁 次 | 頁18-24 |
分類號 | 418.29 |
關鍵詞 | 免疫查核點抑制劑; 免疫相關不良反應; Immune-related adverse events; ICPis; irAEs; |
語 文 | 中文(Chinese) |
中文摘要 | 免疫查核點抑制劑 (immune checkpoint inhibitors, ICPis) 因為驚人的療效,在癌症治療上引起了新的革命。雖然 ICPis 的效果讓人驚艷,但抑制免疫查核點的作用也會影響非腫瘤細胞的免疫恆定,導致免疫相關不良反應 (immune-related adverse events,irAEs) 的發炎性副作用。由於 irAEs 與細胞毒性藥物及標靶藥物的副作用截然不同,醫療人員對 irAEs 較不熟悉;但隨著 ICPis 使用族群與治療對象增加,醫療人員將面對更多此類藥物以及相關副作用的問題。因此所有醫療人員應對 irAEs 有更多的認識與了解,才能快速辨別與處理。 |
英文摘要 | Immune checkpoint inhibitors (ICPis) has revolutionized the treatment of cancer therapy with their remarkable benefit. Unfortunately, the inhibition of immune checkpoints also disturb immune system on nontumor cells, leads to "immune-related adverse events (irAEs)" which cause inflammatory side effects. Because irAEs have toxicity profiles that differ from chemotherapy or targeted therapy, many clinicians are less familiar with irAEs. With the increasing success and popularity of ICPis, clinicians will encounter increasing numbers of these medications and side effects. Therefore, all clinicians should be aware of the possibility of irAEs to allow for early diagnosis and treatment. |
本系統中英文摘要資訊取自各篇刊載內容。